Your Health, We Care
Release date: 2026-02-03 16:26:33 Article From: Lucius Laos Recommended: 13
Nintedanib is a small-molecule tyrosine kinase inhibitor that binds to growth factor receptors and inhibits the proliferation of fibroblasts.
Take this medication orally with warm water. Take it at the same time each day as directed on the prescription label. Do not cut, crush, or chew this medication. Swallow the capsules whole. Take this medication with food. Continue taking it unless instructed otherwise by your healthcare team.
If you accidentally come into contact with the medication inside the capsules, wash your hands immediately.
Consult your healthcare team before giving this medication to children. Special care may be required.
Overdose: If you think you have taken too much of this medication, contact a poison control center or emergency room immediately.
Note: This medication is for your personal use only. Do not share it with others.
If you miss a dose, skip the missed dose. Take your next dose at the regular time. Do not take an extra dose or a double dose to make up for the missed one.
Nintedanib may cause birth defects or fetal death. Women should not become pregnant while taking nintedanib. Women of childbearing potential should undergo a pregnancy test before starting nintedanib treatment.
Women of childbearing potential should use effective contraceptive methods at the start of treatment, during treatment, and for at least 3 months after stopping treatment. Discuss with your doctor which contraceptive method is right for you during this period.
Contraceptives may be less effective in women who experience vomiting, diarrhea, or other conditions that affect drug absorption. If you have any of these conditions, consult your doctor about the appropriate effective contraceptive method for you.
If you become pregnant or think you may be pregnant while taking nintedanib, inform your doctor immediately.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：802025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3732024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：712025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：932025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：872025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1022025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：992025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：992025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
